%PDF-1.5
%
1 0 obj
< 23 months occurring in nearly 25% of advanced melanoma patients. The overall disease control rate \(CR, PR and SD\) was 83.7%, including CR in very advanced cases. These results, in a largely unselected population of advanced metastatic melanoma patients, compare very favourably with other regimens, and notably were associated with minimal, if any, toxicity. Further analysis of this approach appears warranted.)/Author(Brendon Coventry, Peter Hersey, Anne-Marie Halligan, Antonio Michele)/CreationDate(D:20110114135938+08'00')>>
endobj
2 0 obj
<>stream
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>stream
h[ݒ㶕MM $HnWͶSflj1HGž?Gn\[[S# x z'z*q&JcF:VOH܅Q>éirCVqj$Vkˮ8\gnUZw44|kBb(ՏOiskaNO_ޭq|ǏybR=ulP4@~iSOMSZP[kRc!or$٪u9
]T_=#`"@oM.`JUQǮݔ iEt@T#IpdO6{FD9ԱxVoհWCWl+Xs#S$grlzܔkIdꊦ#~dTŁZm_<[se.P.(`6WŠAݮO{hp\'̇C"ᗫuz!Gna|E.ҭz+:|"oz92<|\ ,?${RՎoZLZsշw=_xJɹA$1( m=L2`Moθ-Evt\Ϫ/k
[W^LO'(8uIA8Z~XzPm)cH}qCKqq?|/{܂2gvWVlGA|#K؍S ICCxר|[@j;໗ٺvb+i@J%`)\UC!:I)b;4
qA-Iї!H!ͷls@&*k<4@Oꡬko=aߠ8o|zcw5fƲAۀ,ۑ|6*4,` !"oqour)V$WT )3+Xĺn_p&hJh`H :=HCԦZi='फ़K:7#]@[@+4Zzw?X@~qg|$Ïd`4*l o{Js%Æ;uB^ʑӧSytug,56oj?^i2#Ҁ}*ݵl;U]]ݺ:զe!~9'"1$sΑlXB6dPI_aUH/eOAzWk \&77`
10⸰lYLo dӿ&O?h į|
|Pƨ@߮V:QQ㊛qW腌QDHm?o'^^u#oDȖ{}Qɥ%e{[Bp U85@$6pں'yaPNW-w(~Ky*8tDo!5~OȎw`eɱ^]&9=Z@)osf @xn &
^FKel['J#Of